Brussels - UNIV Saint-Luc

Brussels 1200

0 studies enrolling now · 12 studies all time

What they study most

Breast Neoplasms, Cholangiocarcinoma, Gastrointestinal Neoplasms, Generalized Pustular Psoriasis, Kidney Disease, Chronic, Leukemia, Myeloid, Acute, Mesothelioma, NUT Carcinoma, Neoplasms, Palmoplantar Pustulosis, Palmoplantar Pustulosis (PPP), Pancreatic Neoplasms

Studies at this site

• A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab — Stopped early
• A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis — Completed
• A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis — Completed
• A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer — Completed
• The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread — Completed
• A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease — Completed
• BI 894999 First in Human Dose Finding Study in Advanced Malignancies — Completed
• Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2) — Completed
• Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE) — Completed
• A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis — Completed
• Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS) — Completed
• Nintedanib (BIBF 1120) in Mesothelioma — Stopped early